Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008

Emerging Infectious Diseases

Volumn 17, Issue 3, 2011, Pages 432-440

  Velásquez, Gustavo E ^a   Yagui, Martin ^b   Peter Cegielski, J ^c   Asencios, Luis ^b   Bayona, Jaime ^d,f   Bonilla, Cesar ^g   Jave, Hector O ^g   Yale, Gloria ^h   Suárez, Carmen ⁱ   Atwood, Sidney ^a   Contreras, Carmen C ^d   Shin, Sonya S ^a,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTO NACIONAL DE SALUD   (Peru)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d SOCIOS EN SALUD   (Peru)

^e PARTNERS IN HEALTH   (United States)

^f DARTMOUTH COLLEGE   (United States)

^g MINISTERIO DE SALUD   (Peru)

^h Laboratorio Regional   (Peru)

ⁱ Direccion de Salud IV Lima Este   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SENSITIVITY; DYSPNEA; FEMALE; HEMOPTYSIS; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PERU; PREVALENCE; RELAPSE; RISK FACTOR; SMEAR; TUBERCULOSIS CONTROL; WEIGHT REDUCTION;

EID: 79952318710     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1703.101553     Document Type: Article

References (26)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report [cited 2010 Jun 5]. http://www.who.int/tb/publications/global/report/2009/update/en/index.html
2. Yagui M, Perales MT, Asencios L, Vergara L, Suarez C, Yale G, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis. 2006;10:838-43.
3. Mitnick CD, Appleton SC, Shin SS. Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med. 2008;29:499-524. DOI: 10.1055/s-0028-1085702
4. Shin SS, Yagui M, Ascencios L, Yale G, Suarez C, Quispe N, et al. Scale-up of multidrug-resistant tuberculosis laboratory servicesx, Peru. Emerg Infect Dis. 2008;14:701-8. DOI: 10.3201/ eid1405.070721
5. Asencios L, Yale G, Yagui M, Quispe N, Taylor A, Blaya J, et al. Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru. Int J Tuberc Lung Dis. 2008;12:743-9.
6. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J. 2005;26:339-50. DOI: 10.1183/09031936.05.00050305
7. Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2005;55:500-5. DOI: 10.1093/jac/dki023
8. Bwanga F, Joloba ML, Haile M, Hoffner S. Evaluation of seven tests for the rapid detection of multidrug-resistant tuberculosis in Uganda. Int J Tuberc Lung Dis. 2010;14:890-5.
9. Angeby KA, Klintz L, Hoffner SE. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol. 2002;40:553-5. DOI: 10.1128/ JCM.40.2.553-555.2002
10. Solis LA, Shin SS, Han LL, Llanos F, Stowell M, Sloutsky A. Validation of a rapid method for detection of M.tuberculosis resistance to isoniazid and rifampin in Lima, Peru. Int J tuberc Lung Dis. 2005;9:760-4.
11. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2008;62:56-64. DOI: 10.1093/jac/dkn139
12. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009;9:67. DOI: 10.1186/1471-2334-9-67
13. Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, Vasquez L, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis. 2008;47:487-95. DOI: 10.1086/590010
14. World Health Organization. Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multidrug resistant tuberculosis. 2010 Jul [cited 2011 Jan 20]. http://www.who.int/tb/laboratory/whopolicy/noncommercialculture/and/dstmethods/july10/revnov10.pdf
15. Ministerio de Salud. Norma técnica de salud para el control de la tuberculosis. Lima (Peru): Ministerio de Salud; 2006.
16. World Health Organization. TB country profile: Peru [cited 2010 Jun 5]. http://www.who.int/GlobalAtlas/predefinedReports/TB/PDF_Files/per.pdf
17. Suárez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359:1980-9. DOI: 10.1016/S0140- 6736(02)08830-X
18. Blaya JA, Shin SS, Yagui MJ, Yale G, Suarez CZ, Asencios LL, et al. A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics. BMC Med Inform Decis Mak. 2007;7:33. DOI: 10.1186/1472-6947-7-33
19. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119-28. DOI: 10.1056/ NEJMoa022928
20. Roberts GD, Goodman NL, Heifets L, Larsh HW, Lindner TH, Mc Clatchy JK, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol. 1983;18:689-96.
21. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth Global Report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: 2002-2007 [cited 2010 Jun 17]. http://www.who.int/entity/tb/publications/2008/drs_ report4_26feb08.pdf
22. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120:1514-9. DOI: 10.1378/chest.120.5.1514
23. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis. 2008;40:888-93. DOI: 10.1080/00365540802342372
24. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, do Valle Dettoni V, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:321-8.
25. Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, et al. Using treatment failure under effective directly observed shortcourse chemotherapy programs to identify patients with multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2000;4:108-14.
26. Banerjee R, Allen J, Lin SY, Westenhouse J, Desmond E, Schecter GF, et al. Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. J Clin Microbiol. 2010;48(10):3779-81. Epub 2010 Aug 11.